Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation

doi:10.4254/wjh.v18.i3.112934

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(24)

(27)

(0)

(618)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 112934
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.112934

Table 1 Cohort characteristics, n (%)

Characteristic	Total (n = 131)	ESLD (n = 72)	nESLD (n = 59)	P value
Sex
Male	96 (73.3)	49 (68.1)	47 (79.7)	-
Female	35 (26.7)	23 (31.9)	12 (20.3)	-
Age at LT, median (IQR)	38 (30, 47)	40 (33, 51)	37 (28, 45)	NS
MELD at LT, median (IQR)	15 (12, 19)	17 (13, 21)	13 (11, 15)	-
PSC phenotype
Large duct	130 (99.2)	72 (98.6)	59 (100.0)	NS
Small duct	1 (0.8)	1 (1.4)	0 (0.0)	-
PSC/AIH overlap	33 (25.2)	24 (33.3)	9 (15.3)	0.025
IBD
UC	86 (65.6)	42 (58.3)	44 (74.6)	-
CD	7 (5.3)	6 (8.3)	1 (1.7)	-
No IBD	38 (29.0)	24 (33.4)	14 (23.7)	NS
Colectomy
Before LT	6 (4.6)	3 (4.2)	3 (5.1)	NS
After LT	14 (10.7)	5 (6.9)	9 (15.3)	-
rPSC
Present	44 (33.6)	23 (31.9)	21 (35.6)	NS
No rPSC	87 (66.4)	49 (68.1)	38 (64.4)	-
Immunosuppression
Tacrolimus	113 (86.3)	63 (87.5)	50 (84.7)	NS
Cyclosporine	18 (13.7)	9 (12.5)	9 (15.3)	-
Donor type
DBD	131 (100.0)	72 (100.0)	59 (100.0)	NS
DCD	0 (0.0)	0 (0.0)	0 (0.0)	-
Anastomosis
Roux-en-Y	78 (59.5)	39 (54.2)	39 (66.1)	NS
Duct-to-duct	53 (40.5)	33 (45.8)	20 (33.9)	-
Follow-up, median (minimum, maximum)	7.85 (4.57, 12.98)	7.81 (5.11, 13.03)	8.20 (4.57, 12.59)	NS

AIH: Autoimmune hepatitis; CD: Crohn’s disease; DBD: Donation after brain death; DCD: Donation after brain death; ESLD: End-stage liver disease; IBD: Inflammatory bowel disease; IQR: Interquartile range; LT: Liver transplantation; MELD: Model for end-stage liver disease; nESLD: No end-stage liver disease; NS: Not significant; PSC: Primary sclerosing cholangitis; rPSC: Recurrence of primary sclerosing cholangitis; UC: Ulcerative colitis.

Full Size Table

Citation: Hlavaty M, Brezina J, Wohl P, Modos I, Bajer L, Fabian O, Vajsova A, Hucl T, Drastich P. Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation. World J Hepatol 2026; 18(3): 112934
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/112934.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.112934

Hlavaty M, Brezina J, Wohl P, Modos I, Bajer L, Fabian O, Vajsova A, Hucl T, Drastich P. Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation. World J Hepatol 2026; 18(3): 112934 [DOI: 10.4254/wjh.v18.i3.112934]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.